Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Johnson & Johnson to $170 from $178 and keeps an Overweight rating on the shares ahead of its Pharma/MedTech investor day on December 5. Wells expects the focus to be on medium- to long-term outlook for Pharma and MedTech, particularly 2025+ growth in Pharma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JNJ:
- Biden Plans to Boost Drug Production Using Cold-War Era Law
- Roku upgraded, Lucid Group downgraded: Wall Street’s top analyst calls
- Gracell initiated with an Outperform at Evercore ISI
- Pfizer (NYSE:PFE) Sued Re:Low-Quality ADHD Drug for Kids
- Suit says J&J, Kenvue failed to flag decongestant issue in IPO, Bloomberg reports